2023
Transitional community adherence support for people leaving incarceration in South Africa: a pragmatic, open-label, randomised controlled trial
Mabuto T, Woznica D, Ndini P, Moyo D, Abraham M, Hanrahan C, Charalambous S, Zack B, Baral S, Owczarzak J, Hoffmann C. Transitional community adherence support for people leaving incarceration in South Africa: a pragmatic, open-label, randomised controlled trial. The Lancet HIV 2023, 11: e11-e19. PMID: 38071994, PMCID: PMC10894448, DOI: 10.1016/s2352-3018(23)00235-7.Peer-Reviewed Original ResearchConceptsHIV treatment servicesUsual care groupTreatment servicesAntiretroviral therapyPrimary outcomeCare groupSouth African National Clinical Trials RegisterDifferentiated service delivery modelsClinical Trials RegisterPeer-led interventionsPassive referralAdherence supportTrials RegisterUsual careAdherence clubsAdverse eventsTreat analysisHIV treatmentMultifactorial barriersCorrectional facilitiesService delivery modelsFinal analysisMental healthMonthsNational InstituteAttitudes towards disposition of cryopreserved sperm in the event of death.
Buller D, Harnisch B, Lyall V, Goltzman M, Neuber E, Bartolucci A, Honig S. Attitudes towards disposition of cryopreserved sperm in the event of death. Canadian Journal Of Urology 2023, 30: 11613-11618. PMID: 37633289.Peer-Reviewed Original ResearchConceptsInfertility diagnosisMale factor infertility diagnosisRetrospective cohort studyInsurance coverageDemographic characteristicsEtiology of infertilityCases of deathCommercial insurance coverageRace/ethnicityCohort studyMale patientsInfertility etiologyFertility centerPatient preferencesDuration of marriagePatientsSubsequent deathFuture deathsFinal analysisConsent formEvent of deathMarital statusDeathReproductive technologiesSignificant differencesBurnout in U.S. hematologists and oncologists: impact of compensation models and advanced practice provider support
Lee A, Masselink LE, De Castro LM, Marshall AL, Connell NT, Dent GA, Fritz J, Homer M, Lucas TL, Naik RP, Nelson M, O'Connell C, Rajasekhar A, Reynolds R, Sharma D, Smith M, Weeks LD, Erikson CE. Burnout in U.S. hematologists and oncologists: impact of compensation models and advanced practice provider support. Blood Advances 2023, 7: 3058-3068. PMID: 35476017, PMCID: PMC10331414, DOI: 10.1182/bloodadvances.2021006140.Peer-Reviewed Original ResearchConceptsCommunity physiciansProvider supportMultivariate logistic regression modelOverall survey response rateClinical support staffCommunity practiceLogistic regression modelsHigh burnoutUS hematologistsSurvey response rateComplete responseFemale genderAMA MasterfileResponse rateSignificant associationHematologistsOncologistsFinal analysisPhysiciansLarge-scale studiesProvider UtilizationPractice surveyAmerican SocietyOne-thirdPhysician compensationAMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles
Li H, Seifer D, Tal R. AMH independently predicts aneuploidy but not live birth per transfer in IVF PGT-A cycles. Reproductive Biology And Endocrinology 2023, 21: 19. PMID: 36739415, PMCID: PMC9898926, DOI: 10.1186/s12958-023-01066-w.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneNumber of embryosEuploid embryosLive birthsOocyte qualityAge groupsSignificant independent predictorsCase-control analysisSART CORS databasePreimplantation genetic testingAMH levelsIVF cyclesIndependent predictorsIVF outcomesOocyte yieldNormal embryosPredictive roleGenetic testingFinal analysisBirthAgeIVFSubset of cyclesHormonePGT
2022
Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial
Schindler E, Sewell R, Gottschalk C, Luddy C, Flynn L, Zhu Y, Lindsey H, Pittman B, Cozzi N, D'Souza D. Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial. Headache The Journal Of Head And Face Pain 2022, 62: 1383-1394. PMID: 36416492, DOI: 10.1111/head.14420.Peer-Reviewed Original ResearchConceptsAttacks/weekPulse regimenCluster headachePsychotropic effectsAttack frequencyPlacebo-controlled studyPlacebo-controlled trialSerious adverse eventsEffects of psilocybinEffect sizeChronic participantsEfficacy outcomesAdverse eventsModerate effect sizeHeadache burdenHeadache disordersTherapeutic effectHeadache diaryPsilocybin administrationDrug sessionsExperimental drugsRegimenPsilocybin-containing mushroomsDefinitive studiesFinal analysisRacial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States
Lu Y, Liu Y, Krumholz HM. Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States. Journal Of The American Heart Association 2022, 11: e025545. PMID: 36172953, PMCID: PMC9673703, DOI: 10.1161/jaha.121.025545.Peer-Reviewed Original ResearchConceptsLow family incomeEligible populationUsual sourceHispanic adultsFinancial barriersEthnic disparitiesNutrition Examination Survey 2015Drug Administration labelingCross-sectional analysisFamily incomePercentage of adultsObese adultsNational HealthUS adultsSemaglutideEligibility criteriaSocial determinantsBlack adultsLarge proportionFinal analysisWeight lossHispanic individualsWhite individualsAdultsRisk reductionPatient cost consciousness in the emergency department
Gaylor JM, Chan E, Parwani V, Ulrich A, Rothenberg C, Venkatesh A. Patient cost consciousness in the emergency department. The American Journal Of Emergency Medicine 2022, 61: 61-63. PMID: 36054987, DOI: 10.1016/j.ajem.2022.08.039.Peer-Reviewed Original ResearchConceptsEmergency departmentPocket costsED patientsLarge academic hospital systemAcademic hospital systemCertain patient demographicsEmergency department settingPerceptions of patientsCost of careMedicare/MedicaidPatient demographicsED careUnscheduled careUninsured patientsDepartment settingPatients' estimatesPatient's abilityEmergency careHigh school educationPatientsPrivate insuranceFinal analysisHospital systemCareConvenience sampleRisk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher V, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald M, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances 2022, 6: 828-847. PMID: 34551064, PMCID: PMC8945306, DOI: 10.1182/bloodadvances.2021004881.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaPost-HCT outcomesRisk classificationAdverse-risk acute myeloid leukaemiaAdverse-risk diseaseFirst complete remissionIntermediate-risk diseaseLeukemia-free survivalAdjusted multivariable analysisCell transplantation outcomesRisk of relapseNovel treatment strategiesCIBMTR databaseComplete remissionOverall survivalMultivariable analysisRisk stratificationTransplantation outcomesMyeloid leukemiaTreatment strategiesPatientsFinal analysisAdverse riskKMT2ADisease
2021
386. A Systematic Review of COVID-19 Transmission Dynamics and Clinical Response on Cruise Ships Globally Between January and October 2020
Willebrand K, Pischel L, Malik A, Jenness S, Omer S. 386. A Systematic Review of COVID-19 Transmission Dynamics and Clinical Response on Cruise Ships Globally Between January and October 2020. Open Forum Infectious Diseases 2021, 8: 294-295. PMCID: PMC8644941, DOI: 10.1093/ofid/ofab466.587.Peer-Reviewed Original ResearchCOVID-19 casesCOVID-19Systematic reviewAttack rateMedian attack rateSARS-CoV-2Full-text articlesMean attack rateClinical responseMedian numberCOVID-19 transmission dynamicsEpidemiologic informationNumber of casesPRIMSA guidelinesDisease controlFinal analysisDiamond PrincessText articlesCOVID-19 outbreakSusceptible populationTransmission dynamicsMEDLINEOutbreakInternational spreadPercent177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP, investigators N. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. The Lancet Oncology 2021, 22: 1752-1763. PMID: 34793718, DOI: 10.1016/s1470-2045(21)00572-6.Peer-Reviewed Original ResearchConceptsMedian overall survivalMidgut neuroendocrine tumorsTreatment-related serious adverse eventsLong-term safety resultsFinal overall survivalPrespecified final analysisPhase 3 trialProgression-free survivalSerious adverse eventsOverall survivalLu-DOTATATE treatmentAdverse eventsNeuroendocrine tumorsLu-DOTATATESecondary endpointsLast patientMyelodysplastic syndromeSafety resultsInteractive web-based response systemControl groupAdvanced midgut neuroendocrine tumorsFinal overall survival analysisWeb-based response systemFinal analysisNETTER-1 trial579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Petrylak D, Perez-Gracia J, Lacombe L, Bastos D, Mahammedi H, Kwan E, Zschäbitz S, Armstrong A, Pachynski R, Goh J, Burotto M, Gravis G, McCune S, Limón J, Retz M, Saad F, Amin N, Li J, Unsal-Kacmaz K, Fizazi K. 579MO CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC). Annals Of Oncology 2021, 32: s629-s630. DOI: 10.1016/j.annonc.2021.08.1092.Peer-Reviewed Original ResearchTRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).
Wong S, Torres-Saavedra P, Saba N, Shenouda G, Bumpous J, Wallace R, Chung C, El-Naggar A, Gwede C, Burtness B, Tennant P, Dunlap N, Mell L, Spencer S, Stokes W, Yao M, Mitchell D, Harris J, Curran W, Le Q. TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). Journal Of Clinical Oncology 2021, 39: 6014-6014. DOI: 10.1200/jco.2021.39.15_suppl.6014.Peer-Reviewed Original ResearchProgression-free survivalPhase II trialOverall survivalStage IIIII trialArm AGrade 3Treatment-related grade 3Randomized phase II trialFinal analysisEffects of chemoradiationBaseline patient characteristicsDays of therapyAdverse event ratesSurvival of patientsCycles of CDDPLog-rank testDual EGFRA vs BMucositis ratesRash ratesPFS ratePrimary endpointSecondary endpointsFrontline therapyA scoping review of rodent-borne pathogen presence, exposure, and transmission at zoological institutions
Hardgrove E, Zimmerman DM, von Fricken ME, Deem S. A scoping review of rodent-borne pathogen presence, exposure, and transmission at zoological institutions. Preventive Veterinary Medicine 2021, 193: 105345. PMID: 34090722, DOI: 10.1016/j.prevetmed.2021.105345.Peer-Reviewed Original ResearchConceptsClinical outcomesRodent-borne pathogensInfectious agentsAggregate literatureBiological AbstractsFeeder rodentsStudy identifiersDiagnostic testsEarly detectionFinal analysisRodent reservoirsZoonotic diseaseAdditional screeningCAB AbstractsRodentsZoonotic pathogensDisease transmissionDiseaseExposureNumber of rodentsJob titlesPathogensSurveillancePathogen transmissionCollection animalsNew Records of Anopheles benarrochi B (Diptera: Culicidae) in Malaria Hotspots in the Amazon Regions of Ecuador and Peru
Viteri D, Herrera-Varela M, Albuja M, Quiroga C, Diaz G, del Aguila Morante C, Ramirez D, Vinetz J, Bickersmith S, Conn J. New Records of Anopheles benarrochi B (Diptera: Culicidae) in Malaria Hotspots in the Amazon Regions of Ecuador and Peru. Journal Of Medical Entomology 2021, 58: 1234-1240. PMID: 33511394, PMCID: PMC8349109, DOI: 10.1093/jme/tjaa293.Peer-Reviewed Original ResearchAge as a risk factor for breast cancer-related lymphedema: a systematic review
Guliyeva G, Huayllani MT, Boczar D, Avila FR, Lu X, Forte AJ. Age as a risk factor for breast cancer-related lymphedema: a systematic review. Journal Of Cancer Survivorship 2021, 17: 246-253. PMID: 33486706, DOI: 10.1007/s11764-021-00994-z.Peer-Reviewed Original ResearchConceptsCancer-related lymphedemaRisk factorsBreast cancer-related lymphedemaPossible risk factorsLevel of evidenceDevelopment of lymphedemaBCRL developmentEffect of agePatient characteristicsDisease entityOvid MEDLINEAverage ageSystematic reviewMedical literaturePatientsRelevant articlesLymphedemaFinal analysisAgeIndividual studiesDifferent findingsEffect relationshipMethodsPubMedReviewMEDLINE
2020
Effect of Enteral Protein Amount on Growth and Health Outcomes in Very-Low-Birth-Weight Preterm Infants: Phase II of the Pre-B Project and an Evidence Analysis Center Systematic Review
Fenton TR, Groh-Wargo S, Gura K, Martin CR, Taylor SN, Griffin IJ, Rozga M, Moloney L. Effect of Enteral Protein Amount on Growth and Health Outcomes in Very-Low-Birth-Weight Preterm Infants: Phase II of the Pre-B Project and an Evidence Analysis Center Systematic Review. Journal Of The Academy Of Nutrition And Dietetics 2020, 121: 2287-2300.e12. PMID: 33358688, DOI: 10.1016/j.jand.2020.11.002.Peer-Reviewed Original ResearchConceptsLow-certainty evidenceProtein intakePreterm infantsEvidence Analysis Center Systematic ReviewSystematic reviewBirth weight preterm infantsLiterature searchWeight gainWeight preterm infantsModerate-certainty evidencePreterm infant formulaMid-arm circumferenceCochrane CENTRAL databasesCertainty of evidenceRisk of biasHigh protein intakeBone mineral contentSignificant differencesEvidence of effectCertainty evidenceHead circumferenceLow intakeHealth outcomesAdequate proteinFinal analysisIdentifying Maltreatment in Infants and Young Children Presenting With Fractures: Does Age Matter?
Mitchell IC, Norat BJ, Auerbach M, Bressler CJ, Como JJ, Escobar MA, Flynn‐O’Brien K, Lindberg DM, Nickoles T, Rosado N, Weeks K, Maguire S. Identifying Maltreatment in Infants and Young Children Presenting With Fractures: Does Age Matter? Academic Emergency Medicine 2020, 28: 5-18. PMID: 32888348, DOI: 10.1111/acem.14122.Peer-Reviewed Original ResearchConceptsFemoral fracturesRib fracturesSystematic reviewAbuse evaluationsMotor vehicle collisionsPercent of childrenLong bone fracturesPubMed/MEDLINEComparable age rangeChild abuse evaluationsChild abuse consultationsHumeral fracturesPediatric patientsCommon injuriesConsensus panelRoutine evaluationSignificant causeEvidence-based frameworkFinal analysisChild abuseAge rangePreverbal childrenMonthsVehicle collisionsYoung childrenExploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministrationPD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Ahmed FS, Gaule P, McGuire J, Patel K, Blenman K, Pusztai L, Rimm DL. PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer. Clinical Cancer Research 2020, 26: 5456-5461. PMID: 32709714, PMCID: PMC7572612, DOI: 10.1158/1078-0432.ccr-20-1303.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntigens, CDAntigens, Differentiation, MyelomonocyticAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenBiomarkers, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingMacrophagesMiddle AgedNeoadjuvant TherapyProgrammed Cell Death 1 ReceptorTriple Negative Breast NeoplasmsConceptsTriple-negative breast cancerPD-L1 expressionNeoadjuvant durvalumabTumor cellsImmune cellsBreast cancerPretreatment core-needle biopsiesPhase I/II clinical trialsPD-L1 protein expressionIMpassion 130 trialCore needle biopsyAmount of CD68Neoadjuvant settingMetastatic settingPD-L1Clinical trialsNeedle biopsyInsufficient tissuePatientsCD68Stromal compartmentQuantitative immunofluorescenceChemotherapyFinal analysisProtein expressionDevelopment of an Accurate Bedside Swallowing Evaluation Decision Tree Algorithm for Detecting Aspiration in Acute Respiratory Failure Survivors
Moss M, White SD, Warner H, Dvorkin D, Fink D, Gomez-Taborda S, Higgins C, Krisciunas GP, Levitt JE, McKeehan J, McNally E, Rubio A, Scheel R, Siner JM, Vojnik R, Langmore SE. Development of an Accurate Bedside Swallowing Evaluation Decision Tree Algorithm for Detecting Aspiration in Acute Respiratory Failure Survivors. CHEST Journal 2020, 158: 1923-1933. PMID: 32721404, PMCID: PMC7674978, DOI: 10.1016/j.chest.2020.07.051.Peer-Reviewed Original ResearchConceptsAcute respiratory failure survivorsNegative predictive valueHigh riskMulticenter prospective studyRisk of aspirationFlexible endoscopic evaluationRecursive partitioning analysisDetection of aspirationARF survivorsEndoscopic evaluationAirway safetyMechanical ventilationMedian timeAspiration riskProspective studyPatientsPredictive valueStudy designFinal analysisStudy proceduresGold standard evaluationSurvivorsThin liquidsExtubationPartitioning analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply